Cystatin C estimated glomerular filtration rate and all-cause and cardiovascular disease mortality risk in the general population: AusDiab study
Elizabeth LM Barr, Anne Reutens, Dianna J Magliano, Rory Wolfe, Zhong X Lu, Ken A Sikaris, Stephanie K Tanamas, Robert Atkins, Steve Chadban, Jonathan E Shaw, Kevan R Polkinghorne
Nephrology | WILEY | Published : 2017
Awarded by National Health and Medical Research Council Training Fellowship -- Australian Research Training
ELM Barr is supported by a National Health and Medical Research Council Training Fellowship -- Australian Research Training (APP1016612). The views expressed in this publication are those of the authors and do not reflect the views of the NHMRC. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. This study was supported in part by the Victorian Government's Operational Infrastructure Support Program, and we thank Melbourne Pathology for their assistance with assaying serum cystatin C. We are also most grateful to the following for their support of the AusDiab study: The Commonwealth Dept of Health and Aged Care, Abbott Australasia Pty Ltd, Alphapharm Pty Ltd, AstraZeneca, Aventis Pharmaceutical, Bristol-Myers Squibb Pharmaceuticals, Eli Lilly (Aust) Pty Ltd, GlaxoSmithKline, Janssen-Cilag (Aust) Pty Ltd, Merck Lipha s. a., Merck Sharp & Dohme (Aust), Novartis Pharmaceutical (Aust) Pty Ltd., Novo Nordisk Pharmaceutical Pty Ltd, Pharmacia and Upjohn Pty Ltd, Pfizer Pty Ltd, Roche Diagnostics, Sanofi Synthelabo (Aust) Pty Ltd., Servier Laboratories (Aust) Pty Ltd, BioRad Laboratories Pty Ltd, HITECH Pathology Pty Ltd, the Australian Kidney Foundation, Diabetes Australia, Diabetes Australia (Northern Territory), Queensland Health, South Australian Department of Human Services, Tasmanian Department of Health and Human Services, Territory Health Services, Victorian Department of Human Services, the Victorian OIS Program and Health Department of Western Australia.